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1. Introduction 
Purines are natural compounds that are found in all of the body's cells. They are the most 
widely distributed kind of N-heterocyclic substances in nature. Purines provide part of 
the chemical structure of some important co-enzymes and the genes of plants and 
animals. These compounds also participate in membrane signal transduction, translation 
and protein synthesis and in the form of purine nucleosides act as neurotransmitters in a 
variety of tissues. Purine base is also present in the structure of some important drugs 
such as 6-mercaptopurine (6-MP) and azathioprine (AZT). In addition, it can be found as a 
nucleobase in some synthetic nucleoside analogues with various pharmacological effects 
including antiviral and antitumor properties and numerous nucleoside analogues and 
their prodrugs were developed for cancer chemotherapy, treatment of patients with 
infections of human immunodeficiency virus (HIV) and infections caused by herpes and 
hepatitis viruses. 
Different enzymes can participate in the metabolism of a drug and alter its function. 
Aldehyde oxidase (EC 1.2.3.1: aldehyde: oxygen oxidoreductase, AO), and xanthine 
oxidase (EC 1.17.3.2: xanthine: oxygen oxidoreductase, XO) which are collectively referred 
as “molybdenum hydroxylases”, are two important cytosolic enzymes that are widely 
distributed throughout the animal kingdom. They are involved in the metabolism of an 
extensive range of exogenous and endogenous compounds with physiological, 
pharmacological and toxicological relevance (Beedham, 2010; Rashidi & Nazemiyeh, 
2010). The reactions catalyzed by AO and XO usually involve a nucleophilic attack at an 
electron-deficient carbon atom adjacent to a ring nitrogen atom in N-heterocyclic 
compounds or found within an aldehyde group. Therefore, purines as N-heterocyclic 
compounds can act as a substrate for both AO and XO (Hall & Krenitsky, 1986; Krenitsky 
et al, 1972, 1986; Rashidi et al., 1997, 2007). In spite of having many physicochemical 
properties in common, AO and XO have different substrate specificities and product 
regiospecificities. In addition, pronounced species variation is present in the levels of 
molybdenum hydroxylases activity, in particular in that of AO (Alfaro et al., 2009; Jones et 
al., 1987; Krenitsky et al., 1984; Rashidi et al., 1997). Therefore, a metabolic pathway 
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mediated by AO or XO could be completely different. This will be more pronounced for 
those compounds that have several sites for oxidation by these two oxidative enzymes. 
Purine nucleus has three sites that could be oxidized by molybdenum hydroxylases. It 
would be difficult, thus, to predict which metabolite will be produced from a purine-
based drug by AO or XO, and the recognition of AO and XO contribution in the 
metabolism of this group of drugs will be a subject for scientific studies. This review 
highlights the involvement of AO and XO in the metabolism of important purine related 
drugs focusing on recent studies. 
1.1 Biological and pharmacological importance of purines  
Purines are an important group of nitrogen-containing compounds that are present in all 
forms of plant and animal life and play a vital role in biological processes. They serve as the 
source of cellular energy in ATP and together with pyrimidine, are the building blocks of 
DNA and RNA. Purines also participate in the structure of the co-enzymes (e.g. NAD+, 
NADP+ and FAD) and they are involved in membrane signal transduction, translation and 
protein synthesis (GTP, cAMP, cGMP, RNA). Over the last decades, a great deal of attention 
has been focused on the extracellular functions of purine nucleosides as neurotransmitters 
in a variety of tissues and different types of specific membrane purinergic receptors have 
been recognized (Di Iorio et al., 1998; Ralevic, 2009). 
Purine nucleus is also present in the structure of some important drugs such as 6-
thioguanine (6-TG), 6-MP and AZT. In addition, it can be found as a nucleobase in some 
synthetic nucleoside analogues which are structurally similar to natural nucleosides. Many 
nucleoside analogues have antiviral and antitumor properties. During the last decades, 
numerous nucleoside analogues and their prodrugs were developed for cancer 
chemotherapy, treatment of patients with infections of human immunodeficiency virus 
(HIV) and infections caused by herpes and hepatitis viruses (Li et al., 2008). In spite of 
having excellent pharmacological activity, they often suffer from a poor oral bioavailability 
due to low intestinal absorption. Therefore, intense research efforts have been focused on 
developing nucleoside analogues prodrugs, mainly in the acyclic form, to improve oral 
absorption (Li et al., 2008).  
1.2 Chemistry of purine 
In 1776, uric acid was isolated in a pure form from urinary calculi (stones), although the 
identification of its structure was not made until about 100 years later. It was this event that 
later was commemorated in the generic name, “purine” (from purum uricum) for the 
heterocyclic system (Hitchings, 1978). Xanthine and hypoxanthine were recognized as other 
members of the system in 1838 and 1850 respectively (Hitchings, 1978). In 1889, the term 
“nucleic acid” was introduced by Altmann and general methods for isolation of nucleic 
acids from various sources were developed by this investigator (Hurst, 1980). Then, purines 
and pyrimidines were discovered in nucleic acids and isolated from calf thymus nucleic acid 
in 1894 (Hurst, 1980). 
The purine nucleus consists of fused pyrimidine and imidazole rings having the 
numbering system shown in Fig. 1 it is an aromatic compound with -deficient ring 
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system; therefore, all its carbon atoms are susceptible towards nucleophilic attack and are 
deactivated towards electrophilic attack. Because of the electron-attracting character  
of the  C=N   moiety, the 2-, 6- and 8-sites favor nucleophilic attack, although the 8-
position would be expected to be less  electron deficient than the two other sites due to 
the electron-releasing character of the -NH- moiety present in imidazole ring.  
The calculated electron densities of the various sites in purine are given in Figure 1. 
Purine is a weak base with an overall pKa = 2.3 (Joule, 1995). According to 13C NMR 
studies all three protonated forms are present in solution but it is suggested that the 
predominant cation is formed by N1 protonation (Joule, 1995). Purine is also a weak acid 
with a pKa of 8.9 (Joule, 1995). 
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Fig. 1. The numbering system and electron densities of purine. Upper and lower numbers in 
(b) are - and -charges respectively (Shaw, 1984) 
1.3 Purines as substrates for aldehyde oxidase and xanthine oxidase 
Different enzymes can participate in the metabolism of a drug either through conversion of 
a prodrug to an active form or elimination of a drug via its metabolic pathway. AO and XO 
as two drug metabolizing enzymes can utilize purines as their substrates (Hall & Krenitsky, 
1986; Krenitsky et al, 1972, 1986; Rashidi et al., 1997, 2007). They have many properties in 
common; both enzymes are large homodimeric proteins with a molecular mass of ~ 300,000 
Da, composed of two identical subunits. Each subunit contains one atom of molybdenum, 
one molecule of enzyme-bound flavin adenine dinucleotide (FAD) and two iron–sulfur 
(2Fe–2S) centers. In spite of these similarities and the existence of an overlap in substrate 
utilization between AO and XO, they have different substrate specificities and product 
regiospecificities. As it was mentioned before, molybdenum hydroxylases can catalyze the 
oxidation of a wide range of aldehydes and N-heterocyclic compounds (Beedham, 2010; 
Rashidi & Nazemiyeh, 2010). Purines are among those N-heterocyclic compounds that may 
be oxidized by AO and XO either as a prodrug converted to its active form (Krenitsky et al., 
1984; Rashidi et al., 1997) or during their catabolic pathways (Rashidi et al., 2007). However, 
the manner of oxidation by these two enzymes could be different from one compound to 
another. 
1.4 Metabolism of endogenous purines 
Purine metabolism in man may be divided into four interfacing compartments which are 
illustrated in Fig. 2 (Palella & Fox, 1991). 
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Fig. 2. Overview of purine metabolism in man (Palella & Fox, 1991) 
a. De novo purine synthesis: The biosynthetic pathway through which non-purine 
precursors are combined to form the purine ring is referred to as de novo purine 
synthesis. These non-purine precursors are provided through dietary intake of amino 
acids (1). The first reaction in this synthetic process is the formation of 5phosphoribosyl-
-1-pyrophosphate which is finally converted to inosine-5’-monophosphate (IMP) in a 
ten step pathway (2).  
b. Nucleotide interconversion: Once IMP is formed it may be metabolized to other purine 
ribonucleotides such as AMP and GMP by interconversion pathways (3).  
c. Salvage of performed purine bases: These ribonucleotides may be converted to 
diphosphate and triphosphate forms which serve as essential substrates for variety of 
pathways (4), or to be broken down to purine bases or nucleosides (5). 
d. Degradation: As a final step in human purine metabolism, nucleosides and purine bases 
are metabolised to uric acid (6) which is excreted primarily in urine with small amounts 
excreted into intestine thereby bacterial uricolysis occurs (7). The conversion of 
hypoxanthine to xanthine and xanthine to uric acid is catalyzed by XO. 
2. Purine-related drugs and their metabolism by molybdenum hydroxylases 
2.1 Thiopurines: 6-mercaptopurine, azathioprine and 6-thioguanine  
Thipurines, 6-MP, AZT and 6-TG, are the analogues of purine nucleosides that serve as the 
backbone of current childhood acute leukemia treatment. They have also been effective 
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immunosuppressive agents for the past half a century and remain the immunosuppressive 
of choice for Crohn’s disease (Ansari et al., 2008; Fotoohi et al., 2010). In the early 1940s, the 
first studies on purine analogues as antimetabolites were begun by Hitchings and his group 
in which 8-azaguanine and 2,6-diaminopurine were found to possess marked anticancer 
activity in experimental tumors (Elion et al., 1951). Subsequently, 6-MP was synthesized by 
Elion and Hutchins in 1951 and found to have a high order of activity against human 
leukemia (Elion et al., 1952); it was successfully employed in the treatment of leukemia in 
man in 1953. This discovery was an important point in the development of antineoplastic 
and immunosuppressive agents. In 1958, the immunosuppressive activity of 6-MP in rabbits 
was demonstrated by Schwartz et al. (1958). Shortly, 6- (1-methyl-4-nitro-5-imidazolyl) 
thiopurine, AZT, was synthesized by the Hitchings–Elion laboratory and shown that this 
analogue of 6-MP acts as a pro-drug and is reduced non-enzymatically in body to 6-MP 
which is converted by sensitive neoplasms to the active form 6-thioinosinate by 
hypoxanthine-guanine phosphoribosyl-transferase (Van Scoik et al., 1985). AZT has a higher 
therapeutic index than 6-MP (Van Scoik et al., 1985). AZT has more potent 
immunosuppressive effect than 6-MP and is preferred drug to prevent or delay graft 
rejection and treat rheumatoid arthritis (Chabner et al., 2001). 6-MP together with 
methotrexate are the drugs of choice in the treatment of childhood acute lymphocytic 
leukemia, especially in those cases where prolonged duration of remission is required 
(Knoester et al., 1993; Van Scoik et al., 1985); however, this thiopurine is not effective for the 
treatment of chronic lymphocytic leukemia, Hodgkings disease or other 
lymphomas/carcinomas (Rider, 2008). 
Although thiopurines have been used for over 50 years, many aspects of their complex 
pharmacology and metabolism remain unclear. However, it has been suggested that (Zimm 
et al., 1984; Chabner et al., 2001) in the cell, 6-MP is converted first to thioinosinic acid, by 
hypoxanthine-guanine phosphoribosyl-transferase which is then metabolized to 
thioguanine ribonucleotide and deoxyribonucleotide; incorporation of these compounds 
into RNA and DNA results in the antitumour effect of the drug. In addition, thioinosinic 
acid can be methylated to 6-methylthioinosinate which like thioinosinic acid is able to 
inhibit glutamine-5-phosphoribosylpyrophosphate amidotransferase, the first enzyme 
unique to the de novo pathway for purine ribonucleotide synthesis. 
The oral bioavailibility of 6-MP in man is low and highly variable (Knoester et al., 1993; 
Meerten et al., 1995), however, this is the usual rout of administration. The mechanism for 
this variability is not fully known but it may be due to a combination of differences in the 
rate of absorption, distribution, elimination and first-pass metabolism of drug (Knoester et 
al., 1993). After intravenous injection, 6-MP undergoes rapid cellular uptake, hepatic 
metabolism, and renal excretion. Approximately 50% of an administered dose of the drug is 
excreted in the urine within 24 hours, with 22% eliminated as unchanged drug (Rider, 2008).  
6-MP, after administration, may enter into either anabolic or catabolic metabolic pathways 
(Lennard et al., 1991; Van Scoik et al., 1985). The anabolic pathway is responsible for 
conversion of 6-MP to its active form, whereas the drug is degraded to inactive forms in the 
catabolic pathway via two major inactivation routes (Fig. 3). One is thiol methylation, which 
is catalyzed by the enzyme thiopurine S-methyltransferase, to form the inactive metabolite 
methyl-6-mercaptopurine. The second route is thought to involve the initial oxidation of 6-
MP to 8-oxo-6-MP followed by conversion to 6-thiouric acid (Elion, 1967; Van Scoik et al., 
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1985). However, Zimm et al., (1984) have identified 6-thioxanthine in the urine samples of 
some patients who received 6-MP by intravenous infusion which may indicate that 6-MP is 
converted to 6-thiouric acid via 6-thioxanthine. The oxidative inactivation of 6-MP has been 
attributed to XO activity in intestinal mucosa and liver. The Km value for the oxidation of 6-
MP by calf liver and bovine milk xanthine oxidase (BMXO) is 20-30 µM (Chalmers et al., 
1969; Krenitsky et al., 1972). 6-MP is also a substrate for rabbit liver AO with a reported Km 
of 1.6 mM (Hall & Krenitsky, 1986). The second catabolic pathway for 6-MP is methylation 
of the sulphur atom catalyzed by thiopurine methyltransferase. 6-Methylmercaptopurine 
then undergoes oxidation at position 8 catalyzed by XO and/or AO (Van Scoik et al., 1985); 
the difference in metabolite profile between oral and intravenous administration may be 
indicative of the significant role of AO in 8-hydroxylation (Beedham, 2002). These metabolic 
pathways are illustrated in Fig. 3. 
N
N N
H
N
SH
N
N
H
N
H
N
SH
N
N N
H
H
N
SH
N
N
H
N
H
N
SH
N
N N
H
N
S
CH3
O
O
N
N N
H
H
N
SH
O
Anabolic pathways
Catabolic pathways
Interacellular anabolic pathwayHypoxanthine-guanine
phosphoribosyltransferase
O
8-Oxo-6-mercaptopurine
6-Thioxanthine
6-Mercaptopurine
Methylmercaptopurine
or
Methyl transferase
8-Oxo-6-methylmercaptopurine
6-Thiouric acid
Sulphate
Glucuronide conjugates,
6-Methylthiouric acide
AO
XO
XO
XO
or
 
Fig. 3. Proposed metabolic pathways for 6-mercaptopurine (6-MP) (Van Scoik et al., 1985; 
Zimm et al., 1984). AO: aldehyde oxidase, XO: xanthine oxidase 
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Although 6-thiouric acid has been detected as the major metabolite of 6-MP after oral 
administration of drug (Elion, 1967; Van Scoik et al., 1985; Zimm et al., 1984), there is no 
direct evidence in the involvement of molybdenum hydroxylases in these oxidative 
reactions and the results obtained from in vitro studies are controversial. 8-Oxo-6-MP (Elion, 
1967; VanScoik et al., 1985), 6-methylmercapto-8-hydoxypurine (Keuzenkamp-Jansen et al., 
1996)  and 6-thioxanthine (Zimm et al., 1984), all have been suggested to be the intermediate 
in the conversion of 6-MP to 6-thiouric acid. Recently, Rashidi et al. (2007) have 
demonstrated that 6- MP is more likely oxidized to 6-thiouric acid via 6-thioxanthine rather 
than 8-oxo-6-MP. The first step which is the rate limiting step is catalyzed solely by XO, 
whereas both XO and AO are involved in the oxidation of 6-thiouric acid to 6-thiouric acid 
(Fig. 4).  
 
6-Mercaptopurine
XO
6-Thioxanthine
XO & AO
Very fast
6-Thiouric acid
 
Fig. 4. Proposed metabolic pathway for the oxidation of 6-mercaptopurine by partially 
purified guinea pig liver fractions (Rashidi et al., 2007). AO: aldehyde oxidase,  
XO: xanthine oxidase 
The metabolism of 6-TG is very similar to that of 6-MP, however, there is a clinically 
important difference between catabolic pathway of these two thiopurines (Fig. 5). Unlike 6-
MP which is first metabolized to 6-thioxanthine by XO and then 6-thiouric acid by both XO 
and AO (Rashidi et al., 2007), 6-TG must first be metabolized by guanine deaminase 
(guanase) to 6-thioxanthine, which is then metabolized to 6- thiouric acid (Evans & Relling, 
1994; Hogarth et al., 2008). As guanase is not as abundant as XO, more of 6-TG is directly 
activated to thioguanine nucleotides without oxidation to the inactive metabolite, 6-thiouric 
acid (Hogarth et al., 2008). This could be a reason for some clinical findings (Lennard et al., 
1993) indicating that in children with acute lymphoblastic leukemia, significantly higher 
concentrations of thioguanine nucleotides are achieved with oral 6-TG therapy compared 
with oral 6-MP therapy (Evans & Relling, 1994). 
In addition, taking into account the important role of XO in the catabolic pathway of 6-MP, 
co-administration of 6-MP and XO inhibitors such as allopurinol can lead to severe forms of 
mercaptopurine toxicity and dosage modification of the drug is necessary, whereas in the 
case of 6-TG dosage modification is not warranted, because the first step of drug 
inactivation is not catalyzed by XO (Hande & Garrow, 1996). 
AO is also involved in the metabolism of 6-TG (Fig. 5). According to Kitchen et al. (1999), 6-
TG can be oxidized to 8-hydroxythioguanine by AO. 8-Hydroxythioguanine has been found 
to be the predominant circulating metabolite in patients receiving continuous i.v. infusion of 
thioguanine and is likely generated by the action of AO (Kitchen et al., 1999).  
AZT can also undergo two different metabolic routes. In the first route, AZT is extensively 
converted to 6-MP which is then metabolized as in Fig. 6. In the second route, AZT may be 
directly oxidized to 8-oxo-azathioprine, catalyzed by AO. Cleavage of 8-oxo-azathioprine by 
glutathione or other nucleophilic compounds gives 8-oxo-6-mercaptopurine which may 
then be oxidized to 6-thiouric acid by XO (Fig. 6). 
www.intechopen.com
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
292 
 
N
N N
H
N
SCH3
H2N
N
N N
H
N
SH
H2N
N
N N
H
N
SH
H2N
N
N N
H
N
SH
HO
N
N N
H
N
SH
HO
6-Methyl-Thioguanine
Thioxanthine
Thioguanine
Thioguanosine 5’-Monophosphate
OH
OH
TPMT
PRPP
HPGT
AO
XO
Guanase
8-Hydroxy-Thioguanine
Thiouric Acid
Guanase
N
N N
N
O
OHOH
SH
H2N
Po4H2C
 
 
Fig. 5. Metabolic pathways of 6-TG. PRPP: phosphoribosyl pyrophosphate, HPGT: 
hypoxanthine-guanine phosphoribosyl transferase, TPMT: thioguanosine monophosphate, 
AO: aldehyde oxidase, XO: xanthine oxidase (from: Kitchen et al., 1999) 
The Km value for the oxidation of azathioprine by rabbit liver AO is 80 µM (Chalmers et al., 
1969), whereas azathioprine is very poor substrate for XO such that kinetic constants have 
been measured competitively against the oxidation of 6-methylaminopurine catalyzed by 
human liver XO (Ki = 340 µM) (Krenitsky et al., 1986). Therefore, it is likely that AZT is 
oxidized by AO in vivo if the drug comes in contact with the enzyme (Chalmers et al., 1969). 
It is estimated that the effects of XO and AO activity leaves only about 16% of the total dose 
of 6-MP available for systemic distribution (Fotoohi et al., 2010). 
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Fig. 6. The metabolic pathways for azathioprine (Van Scoik et al., 1985). AO: aldehyde 
oxidase, XO: xanthine oxidase 
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2.2 Famciclovir 
Famciclovir 2-[2-(2-Amino-9H-purin-9-yl) ethyl]-1,3-propanediol diacetate (ester) is a 
synthetic guanine derivative which is metabolized to the potent antiviral compound 
penciclovir. Penciclovir is active against herpes simplex virus (HSV) types 1 and 2, varicella 
zoster virus (VZV), Epstein-Barr virus (EBV), and hepatitis B (Perry & Wagstaff, 1995).  
The mechanism of action of penciclovir is similar to that of aciclovir. Both drugs are 
selectively phosphorylated in virus-infected cells to a monophosphate ester by thymidine 
kinase, followed by further phosphorylation to a triphosphate ester which inhibits virus 
DNA polymerases (Vere Hodge & Cheng, 1993). However, the concentration of 
triphosphate ester of penciclovir within infected cells is higher than that of aciclovir and it 
has a more prolonged intracellular half-life in cells infected with HSV (10-20 hours) and 
VZV (7-14 hours) compared to aciclovir triphosphate (1 hour) (Perry & Wagstaff, 1995; Vere 
Hodge & Cheng, 1993). Like aciclovir, penciclovir has very low oral bioavailibility, but its 
prodrug, famciclovir, is absorbed rapidly and extensively after oral administration, and little 
or no parent compound can be detected in plasma or urine (Mondal, 2008). The absolute 
bioavailability of penciclovir is about 77% (Pue & Benet, 1993), which is about four times 
higher than that of aciclovir (Murray, 1995). 
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Fig. 7. The major metabolic pathway of famciclovir in man (Vere Hodge et al., 1989) 
Metabolism of famciclovir involves sequential hydrolysis of both acetyl groups to give 6-
deoxypenciclovir which can be oxidized to penciclovir (Fig. 7); however, both in vivo and in 
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vitro studies have also shown that penciclovir is the major metabolite of famciclovir 
metabolism (Pue & Benet, 1993; Pue et al., 1994; Rashidi et al., 1997). Although the oxidative 
step was initially attributed to XO, on the basis of studies performed with 6-deoxyaciclovir and 
a structural similarity between 6-deoxypenciclovir and guanine which is a substrate of XO 
(Harrell et al., 1993; Krenitsky et al., 1984; Vere Hodge et al., 1989), later studies demonstrated 
that AO is the major enzyme in oxidative conversion of famciclovir to penciclovir (Clarke et 
al., 1995; Rashidi et al., 1997).  
According to Rashidi et al. (1997), both famciclovir and 6-deoxypenciclovir are 
predominantly oxidized at carbon 6 by human, guinea pig and rat hepatic AO, whereas 
the major metabolites with rabbit enzyme are 8-oxo- and 6-oxo-derivatives with the 
former metabolite having higher contribution. 6-Deoxypenciclovir is oxidized only at the 
6-position by rat liver and BMXO. Famciclovir is a better substrate than 6-
deoxypenciclovir for hepatic AO from all species tested (Table 1). The oxidation rate of 
both compounds is comparable with probe substrates of AO such as phenanthridine and 
phthalazine (Rashidi et al., 1997).  
 
 
 
Enzyme fraction 
6-Deoxypenciclovir Famciclovir 
Km 
(mM) 
Vmax 
(nmol/mg/min)
Vmax/Km 
(ml/min/mg)
Km 
(mM) 
Vmax 
(nmol/mg/min) 
Vmax/Km 
(ml/min/mg) 
Human Liver AO  
(N = 1-2) 
0.42 16 0.038 0.15 61 0.407 
Guinea pig liver 
AO  (N = 3-5) 
0.41± 
0.01a 
209±38 0.510 0.17±0.01 439±48 2.582 
Rabbit liver AO  
(N = 2) 
0.44 114 0.259  NDb  
AO-Active rat 
enzyme (N = 3)a 
0.37±0.05 26±6 0.070 0.08±0.02 41±10 0.506 
AO-Deficient rat 
enzyme (N = 3)a 
0.26±0.01 4±2 0.015  NRc  
BMXO (N = 2) 0.90 155 0.172  NR  
a Mean±SD 
b ND: Not determined  
c NR: No reaction 
Table 1. Kinetic parameters for 6-oxo-metabolite formation by partially purified guinea pig, 
human, rabbit, rat liver aldehyde oxidase (AO) and bovine milk xanthine oxidase (BMXO) 
determined by HPLC (Rashidi et al 1997) 
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Although 6-deoxypenciclovir is oxidized very slowly by rat liver XO and BMXO, 
famciclovir did not serve as a substrate for either enzyme. In Figures 8-10, the metabolic 
pathways of famciclovir with different enzyme fractions have been illustrated. 
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Fig. 8. The oxidative metabolic pathways of 6-deoxypenciclovir catalyzed by partially 
purified guinea pig, aldehyde oxidase-active rat and human liver fractions (Rashidi, 1996; 
Rashidi et al., 1997). AO: aldehyde oxidase, XO: xanthine oxidase 
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Fig. 9. The oxidative metabolic pathways of 6-deoxypenciclovir catalyzed by partially 
purified rabbit liver fractions (Rashidi, 1996; Rashidi et al., 1997). AO: aldehyde oxidase, XO: 
xanthine oxidase 
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Fig. 10. The oxidative metabolic pathways of 6-deoxypenciclovir catalyzed by partially 
purified aldehyde oxidase-deficient rat liver fractions (Rashidi, 1996). XO: xanthine oxidase 
2.3 Ganciclovir 
Ganciclovir is an acyclic nucleoside analog of 2’-deoxyguanosine from which the 2’ carbon 
has been deleted. It is used for the treatment of cytomegalovirus (CMV) infections, most 
commonly retinitis, colitis, and esophagitis, in immunocompromised patients and is 
administered to transplant patients at risk for CMV retinitis (Mondal, 2008; Physician’s Desk 
Reference, 2000).  
Ganciclovir is much more effective than aciclovir against CMV and HSV (De Clercq & Field, 
2006; Noble & Faulds, 1998), although it has greater potential toxicity (Crumpacker, 1996). It 
is more easily phosphorylated in CMV infected cells than aciclovir and its triphosphate has 
a 5-fold higher affinity for CMV DNA polymerase than aciclovir triphosphate (Krogsgaard-
Larsen, 1992). Ganciclovir is also active against VZV and EBV; however, it causes 
neutropenia and its clinical use is restricted to the treatment of CMV infections in 
immunocompromised patients (Krogsgaard-Larsen, 1992). 
Like aciclovir, the absorption of ganciclovir following oral administration is low. Its absolute 
bioavailability after oral administration of 1000 mg of ganciclovir capsules three times a day 
was approximately 8.5% (Anderson et al., 1995). To overcome this problem, in accordance 
with the prodrug approaches, various analogues of ganciclovir were synthesized. One of the 
strategies used was the synthesis of C-6 deoxy 2-aminopurine prodrugs of ganciclovir. 
Significant success with this strategy had been achieved previously by aciclovir. The 
dipivalate ester of 6-deoxyganciclovir was one of the prodrugs of ganciclovir that was 
produced using this strategy (Krasny et al., 1995). The dipivalate ester was introduced to 
increase lipophilicity of the molecule. Because of chemical similarity of aciclovir and 
ganciclovir, it was also expected that the 6-deoxy prodrug would be converted to 
gannciclovir. According to preclinical studies in rats, a 7-fold enhancement in oral 
bioavailability of the compound was observed and the prodrug was rapidly converted to 
ganciclovir and 6-deoxy ganciclovir in vivo; however, the 6-deoxy ganciclovir was not 
oxidized to ganciclovir by XO. Rat liver sometimes has insufficient XO activity and the 
results obtained from this animal model cannot be extrapolated to human, in particular with 
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nucleobase antiviral agents (Rashidi et al., 1997). Therefore, the involvement of AO or XO in 
conversion of 6-deoxyganciclovir produced from its dipivalate ester analogue to ganciclovir 
cannot be ruled out and further studies may be required. 
The other example of the use of prodrug approach to increase the oral bioavailability of 
ganciclovir is HOE 602, the bis-isopropyl ether of 6-deoxy ganciclovir. HOE 602 is a 
nucleobase analog of ganciclovir with high therapeutic efficacy against HSV and MCMV 
infections in mice (Winkler et al., 1990). Pharmacokinetic studies in mice and rhesus 
monkeys indicated that this prodrug is converted to ganciclovir via a three-step pathway 
(Fig. 11) and yields a 4 to 21-fold increase in exposure after oral administration in monkeys 
compared to an equivalent oral dose of ganciclovir (Winkler et al., 1990). The first step, 
oxidation of the 6-aminopurine moiety to guanine, is mediated by XO (Winkler et al., 1990). 
However, no further studies of HOE 602 have been published (Li et al., 2008). 
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Fig. 11. Conversion of HOE 602 prodrug to ganciclovir (Winkler et al., 1990). XO: xanthine 
oxidase 
Valganciclovir, a valine ester of ganciclovir, is another example of prodrug approach to 
overcome the poor oral absorption of ganciclovir (Maag, 2002). Following oral 
administration of valganciclovir in human, the absolute bioavailability of ganciclovir could 
be 10-fold higher than that from oral ganciclovir (Jung & Dorr, 1999; Pescovitz et al., 2000). 
According to these studies, no significant amount of the prodrug was detected in plasma 
which may be indicative of rapid and complete hydrolysis of valganciclovir to ganciclovir in 
vivo (Li et al., 2008).  
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Conversion of valganciclovir to ganciclovir is a hydrolytic reaction and therefore is not 
dependent to molybdenum hydroxylases. However, C-8 carbon in both valganciclovir and 
ganciclovir, like other purine-based antiviral agents such as 6-deoxypenciclovir and 
aciclovir, is susceptible for oxidation by these oxidative enzymes which is subject for further 
studies. Interestingly, according to Krasny et al. (1995), after oral administration of 
dipivalate ester of 6-deoxyganciclovir to cynomolgus monkey, but not rat, the 8-hydroxy 
analogs of ganciclovir and 6-doxyganciclovir are also detected alongside of other 
metabolites. 
2.4 Aciclovir and valaciclovir 
Acyclovir, 9-[(2-hydroxy ethoxy) methyl] guanine is a guanosine analogue antiviral agent 
that has a high therapeutic index. It was the first specific antiviral drug described in the 
early 1980s (Dollery, 1999) and then the spectrum compound of the first aciclovir were 
boarded to vital therapies for DNA virus and retrovirus infections (Field & De Clercq 2004; 
De Clercq & Holy, 2005). Aciclovir is initially phosphorylated to a monophosphate 
derivative by a virus-specific thymidine kinase, and not by the thymidine kinase of 
uninfected cells (Rajalakshmi et al., 2010) and then to a triphosphate which inhibits 
competitively DNA synthesis in the infected cells. Phosphorylation does not occur in 
healthy cells which accounts for its strong selectivity of action (Clercq & Holy, 2005). 
Consequently, the amount of aciclovir triphosphate formed in the virally infected cells is 40-
100 times greater than that in normal uninfected cells (Rajalakshmi et al., 2010). Aciclovir is a 
potent and selective inhibitor of herpes virus DNA replication. It acts as a substrate for the 
enzyme viral DNA polymerase in competition with normal deoxy adenosine triphosphate 
and results in complete and irreversible inhibition of herpes virus DNA polymerase and 
viral DNA chain termination (Rajalakshmi et al., 2010). 
Clinically, aciclovir has been found effective against all types of HSV and VZV but not 
against other species of viruses (Hirsch & Schooley, 1983). In spite of its effective antiviral 
activity, aciclovir has some important limitations. Firstly, it is significantly less effective 
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against VZV than against HSV (Safrin & Phan, 1993) (Easterbrook & Wood, 1994). 
Furthermore, some cases of HSV and VZV isolates resistant to aciclovir have been 
reported(Safrin & Phan, 1993) (Easterbrook & Wood, 1994).  In addition, aciclovir has 
relatively low (15-20%) and unpredictable oral bioavilability (Easterbrook & Wood, 1994) 
(de Miranda & Blum, 1983) resulting in the need for frequent high doses or intravenous 
therapy in conditions where high plasma aciclovir levels are necessary to inhibit less 
sensitive viruses as in like VZV (de Miranda & Burnette, 1994; Safrin & Phan, 1993). 
Consequently, many attempts have been made to improve aciclovir efficiency when given 
orally in humans or to find new successors to aciclovir. Development of a prodrug of 
aciclovir with a better absorption from the gastrointestinal tract and then conversion in vivo 
to aciclovir has been one of the most common strategies used to achieve this goal (Burnette, 
T.C. & de Miranda 1994; Hay CM, Reichman 2008; Krenitsky et al., 1984).   
One such prodrug is 6-deoxyaciclovir or desciclovir, 2-amino-9-[2-hydroxyethoxy) methyl]-
9H-purine. 6-Deoxyciclovir is an analog of aciclovir which is 18 times more water soluble 
than aciclovir (Krenitsky et al., 1984). The prodrug is extensively absorbed following oral 
administration to healthy volunteers and converted to aciclovir in vivo by the XO; however, 
XO cannot further oxidize aciclovir (Fig. 12) (Krenitsky et al., 1984). On the other hand, 
aciclovir is hydroxylated at C-8 by AO, but this enzymatic reaction is a minor metabolic 
pathway in patients (Beedham, 1997). 
Although 6-deoxyaciclovir has been reported as XO-activated prodrugs (Krenitsky et al., 
1984; Jones et al., 1987), the compound is a better substrate for AO than XO (Table 2). Like 6-
deoxypenciclovir, 6-deoxyaciclovir is oxidized to 8-oxo-metabolite as the major metabolite 
by rabbit liver AO (Fig. 13) and its Vmax/Km value is 57-fold higher than that of BMXO 
(Krenitsky et al., 1984). It has been reported that allopurinol was less effective in inhibition 
of 6-deoxyaciclovir oxidation to aciclovir in isolated perfused Sprague-Dawley rat livers 
(Jones et al., 1987) whose liver AO is very variable. The ratio of 8-oxo-metabolite to 6-oxo-
metabolite (aciclovir) from the oxidation of 6-deoxyaciclovir by rabbit liver AO is 95 to 5 
(Krenitsky et al., 1984). Although the bioavailability of 6-deoxyaciclovir was improved, 
further development of the prodrug was terminated due to the chronic toxicity problems 
highlighted in animal studies (de Miranda P & Burnette, 1994). 
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Fig. 12. 6-Deoxyaciclovir as a prodrug of aciclovir is activated by xanthine oxidase (XO) 
(Krenitsky et al., 1984) 
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Fig. 13. Metabolism and inactivation of 6-deoxyaciclovir by rabbit liver aldehyde oxidase 
(Krenitsky et al., 1984) 
AO converts 6- Deoxyaciclovir to 8-hydroxy-6-deoxyaciclovir and aciclovir with the ratio of 
95 to 5 respectively, and both of them are turned more oxidase to 8-hydroxyaiclovir 
(Krenitsky et al., 1984).  
Valaciclovir, 2-[2-amino-1, 6-dihydro-6-oxo-9H-purin-9-yl-methoxy] ethyl valinate 
hydrochloride, is another oral prodrug of aciclovir with an oral bioavailibility of higher than 
that of acyclovir (Burnette, T.C. & de Miranda 1994; Hay CM & Reichman, 2008). 
Valaciclovir is well absorbed following oral administration and is rapidly converted to 
aciclovir by hydrolysis of the valyl ester during first pass intestinal and/or hepatic 
metabolism (Burnette, T.C. & de Miranda, 1994; de Miranda, P. & Burnette, 1994). Therefore, 
the mechanism of action and spectrum of activity of valaciclovir are the same as that of 
acyclovir (Rajalakshmi et al., 2010). 
2.5 Carbovir 
Carbovir is a carbocyclic guanosine derivative with a potent and selective inhibitory effect 
on HIV-1 replication (Vince et al., 1988). As its oral bioavailability is low (Huang et al., 1991), 
its prodrug, 6-deoxycarbovir was synthesized in attempt to increase its oral absorption. The 
chemical structure of 6-deoxycarbovir is very similar to that of 6-deoxypenciclovir and 6-
deoxyaciclovir. Like 6-deoxyaciclovir, 6-deoxycarbovir has been reported as XO-activated 
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prodrug (Vince et al., 1995), but it is also a better substrate for AO than XO (Table 2). 6-
Deoxycarbovir is oxidized at C-8 position and 8-hydroxy-6-deoxycarbovir is the main 
metabolite produced from incubation of 6-deoxycarbovir with rabbit liver AO, but with 
guinea pig liver AO, 6-hydroxylation is the major metabolic pathway and carbovir is 
produced as almost the only oxidative metabolite.  
8-Hydroxy-6-deoxyaciclovir lacks appreciable activity against herpes simplex type I in vitro 
(Krenitsky et al., 1984). As substitution at carbon 8 generally results in loss of antiviral 
activity (Beedham, 1997), 8-hydrox-6-deoxycarbovir is expected to be dvoid of antiviral 
activity. It is likely that AO from other sources like guinea pig liver, which is a better animal 
model for human liver AO (Rashidi, 1996), acts as the main enzyme in oxidative conversion 
of 6-deoxyaciclovir to aciclovir as it is the case with 6-deoxypenciclovir and 6-
deoxycarbovir. The assay of 6-deoxyaciclovir oxidation by hepatic AO from species such as 
guinea pig and human and pharmacokinetics of 6-deoxyaciclovir following administration 
of the compound should be subject to further studies. 
 
Enzyme 
fraction 
6-Deoxypenciclovir  6-Deoxycarbovir  6-Deoxyaciclovir 
Km 
(mM) 
6-oxo-metabolite
/ 
8-oxo-metabolite
 
 
Km 
(mM) 
6-oxo-metabolite 
/ 
8-oxo-metabolite 
 
 
 
Km 
(mM) 
6-oxo-metabolite 
/ 
8-oxo-metabolite 
Guinea pig 0.41 27  0.40 100  ND ND 
Rabbit 0.44 0.9  0.11 0.3  0.06 0.05 
Rat liver XO 0.26 a  0.22 a  ND ND 
BMXO 0.90 a  ND ND  0.9 a 
a: 6-Oxo-metabolite was the only metabolite produced. 
ND: Not determined 
Table 2. The Km value for the formation of 6-oxo-metabolite and the ratio of 6-oxo- to 8-oxo-
metabolite for the oxidation of 6-deoxypenciclovir, 6-deoxycarbovir and 6-deoxyaciclovir 
catalyzed by guinea pig, rabbit, rat liver xanthine oxidase (XO) and bovine milk xanthine 
oxidase (BMXO) (Krenitsky et al., 1984; Rashidi 1996; Rashidi et al., 1997). 
2.6 Vidarabine  
Vidarabine (9-β-D-Arabinosyladenine, adenine arabinoside, Ara-A, Vira-A), a marine-
derived drug has been shown to have antitumor activity. However, it has become more 
notable for its antiviral activity with a high therapeutic index (Hansel et al., 2004; Hirsch & 
Schooley, 1983). In the 1964, the first study on the antiviral activity of vidarabine was 
explained by Private de Grilhe and De Rudder (Private de Grilhe & De Rudder, 1964). 
Following, Whiley described vidarabine activity in the treatment of herpes encephalitis and 
the other herpes infection in newborns (Field & De Clerq, 2004). Vidarabine possess 
significant activity against infections caused by herpes viruses, pox viruses, rhabdoviruses, 
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hepadnaviruses, the vaccinia virus, VZV, and some RNA tumor viruses. Although 
vidarabine is supplanted by acyclovir and other analogs for most applications, it is still used 
as an alternative therapy for acyclovir-resistant HSV and VZV infections (Gentry et al., 
2008). 
However, vidarabine is extensively deaminated in the body by adenosine deaminase (ADA) 
to 9-β-D-arabinofuranosylhypoxanthine (hypoxanthine arabinoside) that has less antiviral 
activity than vidarabine, which is a major limitation in its clinical use (Shen et al., 2009; 
Shope et al., 1983; Sloan et al., 1977). Inhibition of ADA by co-administration of modified 
purine analogues with vidarabine, such as deoxycoformacine, can improve the therapeutic 
effect of vidarabine (Bryson et al., 1974, 1976).  In addition, vidarabine has limited lipid 
solubility which the low delivery from cell membrane and very low solubility in water 
(about 0.47 mg/ml), therefore, the large fluid volumes is needed for intravenous 
administration (Baker et al., 1978; Hirsch & Schooley, 1983; Whitley et al., 1980). 
Vidarabine is a nucleoside analog; therefore, it has to be phosphorylated and to be active. It 
is phosphorylated to its monophosphate, di- and triphosphate nucleotides which during the 
synthetic (S) phase inhibit DNA polymerase and strongly in the virus such as herpes, 
vaccinia and varicella zoster viruses than in the host cells (Dicioccio & Srivastava, 1977; 
Doering et al., 1966; Rose & Jacob, 1978; Shipman et al., 1976). As well, vidarabine is 
integrated into RNA in virus and inhibit RNA polyadenylation reaction (Rose & Jacob, 
1978).  
In mammalian cell, vidarabine is rapidly converted by ADA to hypoxanthine arabinoside 
which has less antiviral activity than vidarabine. Hypoxanthine arabinoside is the major 
metabolite of vidarabine is excreted renally and biotransformed by XO to xanthine 
arabinoside (Fig. 14) (Connor et al., 1975; Friedman & Grasela, 1981; Hirsch & Schooley, 
1983; Shen et al., 2009). Allopurinol as an inhibitor of XO can interfere with the metabolism 
of vidarabine and, therefore, co-administration of allopurinol with vidarabine should be 
avoided or used with caution (Woster, 2007). The role of AO in this metabolic pathway, in 
particular oxidation of xanthine arabinoside at C-8, has not been investigated and could be a 
subject for future studies.  
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Fig. 14. The biotransformation of vidarabine in mammalian cells. Vidarabine is converted to 
hypoxanthine arabinoside through deamination by adenosine deaminase (ADA), followed 
by oxidation to xanthine arabinoside by xanthine oxidase (XO) (Connor et al., 1975; 
Friedman & Grasela, 1981; Gannon et al., 1984; Shen et al., 2009). 
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2.7 Theophylline 
Theophylline (1,3-dimethylxanthine) is a methylxanthine which is widely distributed in 
nature. It is widely used as a bronchodilator agent for the treatment of various asthmatic 
and pulmonary conditions under a variety of brand names and is one of the most widely 
prescribed drugs for the treatment of airway diseases worldwide (Barnes, 2003). 
Theophylline acts as an effective drug in clinical trials against air way narrowing and 
prevents wheezing, cough, shortness of breath and difficulty breathing which is caused by 
asthma and different lung disease. It is also helpful in patient with chronic obstructive 
pulmonary disease (COPD) including chronic bronchitis and emphysema which opens air 
way lung to make breach easer (Aronson et al., 1992; Pauwel, 1987; Vielhaber & Kavuru, 
2001).  
Theophylline is metabolized in the human liver through N-1 or N-3 demethylation followed 
by hydroxylation at C-8 producing three main products including 3-methylxanthine (3MX), 
1-methyluric acid (1MU) and 1,3-dimethyluric acid (1,3DMU) (Fig. 15) (Brikett et al., 1983; 
Lu et al., 2003; Yao et al., 2001). It is thought that cytochrome P450 1A2 (CYP1A2) is the most 
important enzyme involved in the catalysis of these reactions (HR et al., 1995; Tjia et al., 
1996). Cytochrome P450 2E1 (CYP2E1) can also mediate C-8 hydroxylation but its 
contribution in this reaction is low (HR et al., 1995; Tjia et al., 1996). 
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Fig. 15. The biotransformation of theophylline through CYP450 family and xanthine oxidase  
(Brikett et al., 1983;  HR et al 1995; Lu et al., 2003; Tjia, et al 1996; Yao et al., 2001). CYP1A2: 
Cytochrome P450 1A2, CYP2E1: Cytochrome P450 2E1, XO: Xanthine Oxidase 
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1-Methyluric acid is the secondary metabolic pathway of theophylline. It is produced 
following a rapid oxidation from 1-methylxanthin by XO (Fig. 15) (Brikett et al., 1983). In 
contrast to the other methylxanthines, 1-methylxanthin is a good substrate for XO 
(Bergmann & Dikstein, 1956; Krenitsky et al., 1972; Lohmann & Miech, 1976) and used as a 
XO activity index for plasma concentration of oxypurinal in man (Graham et al., 1996). The 
involvement of XO in the metabolism of theophylline has also been used for the 
construction of amperometric enzyme electrodes to quantitative measurement of 
theophylline (Stredansky et al., 2000). Allopurinal as a potent inhibitor of XO activity 
decreases the formation of 1-methyleuric acid from the 1-methylxanthine in theophylline 
oxidation (Brikett et al., 1983; German DC, 1986). 
3. Conclusion 
Drug metabolism is one of the important factors that may play a major role in drug 
development and toxicity. AO and XO are two molybdenum-containing enzymes that are 
involved in the metabolism of an extensive range of aldehydes and N-heterocyclic 
aromatic compounds (Beedham, 1997; Rashidi & Nazemiyeh, 2010). Although the 
importance of molybdenum hydroxylases in drug metabolism has usually been 
overshadowed by that of CYP450 as the most important drug metabolizing enzyme 
system, we will witness a significant increase in the importance of XO and AO in drug 
metabolism over the next decade (Alfaro et al 2009; Obach et al., 2004). Purines as  
N-heterocyclic compounds, thus, can serve as substrate for AO and XO and the 
importance of molybdenum hydroxylases in the metabolism of purines and also the 
development of purine related prodrugs has been demonstrated by several authors 
(Clarke et al., 1995; Kitchen et al., 1999; Krenitsky et al., 1984; Rashidi et al., 1997, 2007; 
Van Scoik et al., 1985). 
The reaction catalyzed by AO and XO involves a nucleophilic attack on an electron-deficient 
sp2-hybridized carbon atom adjacent to a ring nitrogen atom in N-heterocyclic compounds. 
Therefore, nitrogen-containing aromatic compounds including purines can act as 
appropriate substrates for XO and AO. Purine nucleus contains several nitrogen atoms and 
is sequentially oxidized at three different positions; in a substituted purine analogue, any of 
these sites could be attacked by AO and XO with varying affinities and/or rates (Beedham, 
2010).  
On the other hand, significant interspecies variations exist in both the number and activity 
of both AO and XO, in particular the former enzyme (Alfaro et al., 2009; Jones et al., 1987; 
Krenitsky et al., 1984; Rashidi et al., 1997). Therefore, not only it is difficult to predict which 
metabolite will be produced from a purine-based drug by AO or XO, but also it would be a 
hard task to recognize which of these two enzymes has a dominant contribution in the 
metabolic pathway. In addition, it would be difficult to find a suitable animal model and 
extrapolate the results obtained from the animal studies to man. 
As it was shown in the previous sections, there are several purine related drugs or 
prodrugs that are metabolized by AO and/or XO; however, the manner of the oxidation 
sites could be completely different for these two enzymes. For example, famciclovir and 6-
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deoxycarbovir are converted to their corresponding active agent by AO with purine 
oxidation occurs at carbon 6. But, rabbit liver enzyme acts differently and attacks mainly 
at carbon 8 of the purine nucleus. In contrast to AO, XO has a little contribution to the 
activation of these purine analogues. Not surprisingly, Krenitsky et al. (Krenitsky et al., 
1972,1984) has shown that the oxidation occurs at carbons 6 and 8 with XO and rabbit 
liver AO, respectively. 6-Deoxyaciclovir which is also a purine-based prodrug is oxidized 
at the 6-position by XO, whereas rabbit enzyme oxidizes 6-deoxyaciclovir to 8-oxo-6-
deoxyaciclovir (Krenitsky et al., 1984). However, it has been found that (Iyer, 1992; 
Rashidi et al., 1997) rabbit liver AO differs to the enzyme from other species in oxidizing 
carbon 8 of 2-NH2-9-substituted purines instead of the 6-position. Therefore, it is more 
likely that 6-deoxyaciclovir is predominantly oxidized to aciclovir by AO from human, 
guinea pig or rat livers which are subject for further studies. This could be case for other 
purine related drugs that their metabolism has been attributed to XO. Conducting 
comparative studies, the like of which has been carried out with famciclovir (Rashidi et 
al., 1997), would be of great value in elucidating the contribution of AO and XO in the 
metabolism of these purine-based agents. In these studies, the selection of an appropriate 
animal model for human AO would be a problem because of the different substrate 
specificity of enzyme from each species.  
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